Bridgeway Capital Management’s Faeth Therapeutics FTH Stock Holding History

Bridgeway Capital Management’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,395	Closed	-$23.5K	–	1244
2024 Q4	$23.5K	Hold	2,395	–	–	﹤0.01%	1181
2024 Q3	$28.6K	Sell	2,395 -1,500	-39%	-$18.3K	﹤0.01%	1239
2024 Q2	$48.3K	Sell	3,895 -1,750	-31%	-$36.4K	﹤0.01%	1225
2024 Q1	$119K	Hold	5,645	–	–	﹤0.01%	1187
2023 Q4	$78.1K	Hold	5,645	–	–	﹤0.01%	1276
2023 Q3	$84.7K	Hold	5,645	–	–	﹤0.01%	1251
2023 Q2	$129K	Hold	5,645	–	–	﹤0.01%	1217
2023 Q1	$169K	Hold	5,645	–	–	﹤0.01%	1131
2022 Q4	$168K	Sell	5,645 -2,500	-31%	-$73.5K	﹤0.01%	1128
2022 Q3	$252K	Buy	8,145 +6,250	+330%	+$246K	0.01%	1089
2022 Q2	$86K	Hold	1,895	–	–	﹤0.01%	1245
2022 Q1	$88K	Buy	+1,895	New	+$151K	﹤0.01%	1266

Other funds holding FTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Bridgeway Capital Management's FTH Position: Q1 2025 in Review

Bridgeway Capital Management sold out of Faeth Therapeutics (FTH) in Q1 2025, closing a stake of 2,395 shares — an estimated $23.5K sold.

Bridgeway Capital Management first reported a position in FTH in Q1 2022 and held it in 12 quarters. The position peaked at $252K in Q3 2022. 20 funds tracked by Wall St. Rank hold FTH as of Q1 2025.

Bridgeway Capital Management reported no remaining Faeth Therapeutics position as of Q1 2025 after selling out during the quarter.
Bridgeway Capital Management sold 2,395 Faeth Therapeutics shares in Q1 2025, an estimated $23.5K.
Bridgeway Capital Management first reported a position in Faeth Therapeutics in Q1 2022 and held it in 12 quarters.
Bridgeway Capital Management's Faeth Therapeutics position peaked at $252K in Q3 2022.
20 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.